Deliver Your News to the World

BiomedReports: The Plot Thickens for HEMISPHERx Biopharma (AMEX:HEB)


LOS ANGELES - 05/29/09 - BioMedReports, the news portal covering the biomedical news is reporting on the reaction to a controversial news article that sent shares of Hemispherx Biopharma plunging late Thursday afternoon.

Immediate reaction from the investment community led BioMedReports to interview the CEO of the company, Dr. William Carter, and as a result, both investors and patients of chronic fatigue syndrome will want to read some of the explosive details highlighted by the new report- including:

How the chief of the U.S. Centers for Disease Control and Prevention’s Chronic Viral Diseases Branch feels about the company’s Ampligen drug product- currently awaiting approval from the FDA.

How the same drug used for CFS has now taken center stage in the fight against so called swine flu (H1N1). The company, in recent days, has moved full force into collaboration with health ministries and scientists in Japan and is officially on the fast track to making some substantial sales of its products to Japan.

Read what publishers of The Pink Sheet- a comprehensive publication for and about the pharmaceutical industry- think about whether Ampligen will be approved or not.

The complete special report can be found at

Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here:


About BioMedReports.Com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content from the healthcare sector.

For more biomedical sector and investment news, go to

Disclosure: No positions.

Certain sections of this report contain forward-looking statements that are based on our reporters’ expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company’s behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.


 FDA Approval
 FDA Decisions
 Clinical Trials
 Hemispherx Biopharma

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.